enVVeno: The Road To Approval Seems Open From Here On [Seeking Alpha]
enVVeno Medical Corporation (NVNO)
Company Research
Source: Seeking Alpha
The path to file for approval in Q4 2024 seems open. The VenoValve targets a significant market of 2.5 million patients in the US alone, with potential pricing between $20,000 and $25,000 per device. enVVeno is well-funded and has strong financial backing, making it a compelling investment opportunity with significant upside potential. Thesis enVVeno Medical Corporation ( NASDAQ: NVNO ) is an undercovered microcap company focusing on treatments for vascular disease Chronic Venous Insufficiency. enVVeno has just released positive topline data of its pivotal trial in 75 patients with chronic venous insufficiency, treated with the VenoValve. Well beyond expectations, 97% of the patients showed clinical improvement at six months, and 74% of them showed a clinically meaningful benefit at that time on the relevant rating scale. The average improvement on that same scale was more than 2.5 times the amount necessary to show clinical benefit. The company is awaiting full twelve-mo
Show less
Read more
Impact Snapshot
Event Time:
NVNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVNO alerts
High impacting enVVeno Medical Corporation news events
Weekly update
A roundup of the hottest topics
NVNO
News
- Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium [Yahoo! Finance]Yahoo! Finance
- Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium Accesswire
- New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 [Yahoo! Finance]Yahoo! Finance
- New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 Accesswire
- enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
NVNO
Sec Filings
- 4/24/24 - Form 8-K
- 3/15/24 - Form 4
- 3/6/24 - Form 8-K
- NVNO's page on the SEC website